CN104955453B - Lfa-1抑制剂制剂 - Google Patents

Lfa-1抑制剂制剂 Download PDF

Info

Publication number
CN104955453B
CN104955453B CN201380071760.5A CN201380071760A CN104955453B CN 104955453 B CN104955453 B CN 104955453B CN 201380071760 A CN201380071760 A CN 201380071760A CN 104955453 B CN104955453 B CN 104955453B
Authority
CN
China
Prior art keywords
formula
compound
solution
composition
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380071760.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104955453A (zh
Inventor
M.纽曼
W.亨克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Ireland Ltd
Original Assignee
Protoplasma Bio-Science Limited-Liability Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104955453(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protoplasma Bio-Science Limited-Liability Co filed Critical Protoplasma Bio-Science Limited-Liability Co
Publication of CN104955453A publication Critical patent/CN104955453A/zh
Application granted granted Critical
Publication of CN104955453B publication Critical patent/CN104955453B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380071760.5A 2012-12-19 2013-12-18 Lfa-1抑制剂制剂 Active CN104955453B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US61/739,609 2012-12-19
US201361758147P 2013-01-29 2013-01-29
US61/758,147 2013-01-29
PCT/US2013/076041 WO2014100135A1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations

Publications (2)

Publication Number Publication Date
CN104955453A CN104955453A (zh) 2015-09-30
CN104955453B true CN104955453B (zh) 2018-09-18

Family

ID=50979140

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380071760.5A Active CN104955453B (zh) 2012-12-19 2013-12-18 Lfa-1抑制剂制剂

Country Status (20)

Country Link
US (2) US11058677B2 (enExample)
EP (2) EP2934510B1 (enExample)
JP (1) JP6373867B2 (enExample)
KR (1) KR101891144B1 (enExample)
CN (1) CN104955453B (enExample)
AU (1) AU2013361579B2 (enExample)
BR (1) BR112015014367B1 (enExample)
CA (1) CA2894170C (enExample)
DK (1) DK2934510T3 (enExample)
EA (2) EA201791321A1 (enExample)
ES (1) ES2846724T3 (enExample)
HU (1) HUE052299T2 (enExample)
IL (1) IL239490B (enExample)
MX (2) MX368876B (enExample)
NZ (1) NZ708821A (enExample)
PL (1) PL2934510T3 (enExample)
PT (1) PT2934510T (enExample)
SI (1) SI2934510T1 (enExample)
WO (1) WO2014100135A1 (enExample)
ZA (2) ZA201504404B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
CN114025759A (zh) * 2019-04-18 2022-02-08 阿祖拉眼科有限公司 用于治疗眼病的化合物和方法
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
EP4232034A4 (en) * 2020-10-21 2024-12-04 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR TREATING EYE DISORDERS
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
WO2025104294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Semifluorinated alkane small molecule lfa-1 antagonist combination compositions for treatment of ocular disorders
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012100109A2 (en) * 2011-01-20 2012-07-26 Advanced Vision Research, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
HK1004520A1 (en) * 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
CN101175488B (zh) * 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
JP5315051B2 (ja) * 2005-07-08 2013-10-16 千寿製薬株式会社 オロパタジンを含む眼科用経皮吸収型製剤
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
JP2011518155A (ja) 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
CA2737475A1 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
CN102176920B (zh) * 2008-11-17 2013-09-18 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
JP5659388B2 (ja) * 2009-06-10 2015-01-28 マイトテック ソシエテ アノニム 医学及び獣医眼科の使用のための医薬組成物
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
PH12012501098A1 (en) * 2009-11-23 2014-10-14 Allergan Inc 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
WO2012111029A2 (en) * 2011-02-18 2012-08-23 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
JP2014518278A (ja) * 2011-06-29 2014-07-28 アラーガン インコーポレイテッド 蕁麻疹の治療に用いるアルカフタジン
WO2013148896A1 (en) * 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012100109A2 (en) * 2011-01-20 2012-07-26 Advanced Vision Research, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer

Also Published As

Publication number Publication date
DK2934510T3 (da) 2021-01-25
US20220000859A1 (en) 2022-01-06
CA2894170A1 (en) 2014-06-26
EP2934510B1 (en) 2020-10-28
BR112015014367B1 (pt) 2022-11-22
KR20150100763A (ko) 2015-09-02
JP6373867B2 (ja) 2018-08-15
PT2934510T (pt) 2021-01-13
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
PL2934510T3 (pl) 2021-07-05
ZA201608069B (en) 2017-11-29
SI2934510T1 (sl) 2021-02-26
ZA201504404B (en) 2020-01-29
BR112015014367A2 (pt) 2017-07-11
US20150320737A1 (en) 2015-11-12
EP2934510A1 (en) 2015-10-28
MX2015007540A (es) 2016-04-13
CA2894170C (en) 2021-08-10
KR101891144B1 (ko) 2018-08-23
IL239490A0 (en) 2015-08-31
CN104955453A (zh) 2015-09-30
AU2013361579A1 (en) 2015-06-18
HUE052299T2 (hu) 2021-04-28
WO2014100135A1 (en) 2014-06-26
EA201791321A1 (ru) 2018-04-30
ES2846724T3 (es) 2021-07-29
MX2019012375A (es) 2020-01-20
MX368876B (es) 2019-10-21
NZ708821A (en) 2020-03-27
JP2016503058A (ja) 2016-02-01
EP3827823A1 (en) 2021-06-02
MX391620B (es) 2025-03-19
IL239490B (en) 2018-12-31
EA201591180A1 (ru) 2015-12-30
HK1214536A1 (zh) 2016-07-29
AU2013361579B2 (en) 2018-05-24
EA028008B1 (ru) 2017-09-29
US11058677B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
CN104955453B (zh) Lfa-1抑制剂制剂
EP3209331B1 (en) Ophthalmic solution
US11793798B2 (en) Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
US20120093876A1 (en) Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
US11331311B2 (en) Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
WO2024028815A1 (en) Ophthalmic composition comprising an anti-allergen and a redness reduction agent
EP3730137B1 (en) Therapeutic agent for glaucoma comprising an fp agonist and timolol
HK1214536B (zh) Lfa-1抑制剂制剂
JP2018188385A (ja) 水性医薬組成物
HK1214963B (en) Lfa-1 inhibitor formulations
EP4565206A1 (en) Ophthalmic composition comprising pilocarpine and a redness reduction agent

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214536

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200611

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: California, USA

Patentee before: Protoplasm Bioscience Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240506

Address after: Ai Erlandubailin

Patentee after: Bausch & Lomb Ireland Ltd.

Country or region after: Ireland

Address before: Basel, SUI

Patentee before: NOVARTIS AG

Country or region before: Switzerland

TR01 Transfer of patent right
IP01 Partial invalidation of patent right

Commission number: 4W115624

Conclusion of examination: On the basis of the claims submitted by the patentee on March 31, 2023, maintain the validity of claims 1-13 of this patent

Decision date of declaring invalidation: 20231117

Decision number of declaring invalidation: 564636

Denomination of invention: LFA-1 inhibitor formulation

Granted publication date: 20180918

Patentee: Bausch & Lomb Ireland Ltd.

Commission number: 4W115629

Conclusion of examination: On the basis of the claims submitted by the patentee on March 31, 2023, maintain the validity of claims 1-13 of this patent

Decision date of declaring invalidation: 20231117

Decision number of declaring invalidation: 564578

Denomination of invention: LFA-1 inhibitor formulation

Granted publication date: 20180918

Patentee: Bausch & Lomb Ireland Ltd.

IP01 Partial invalidation of patent right